Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis
Clinical Scorecard: Impact of Glucagon-Like Peptide-1 Receptor Agonists on Cancer Outcomes and Biological Mechanisms in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Type 2 Diabetes Mellitus
Key Mechanisms
GLP-1 receptor activation influences intracellular signaling pathways involved in cell proliferation, survival, and apoptosis.
Target Population
Adults with Type 2 Diabetes Mellitus using GLP-1 receptor agonists.
Care Setting
Clinical evaluation of cancer outcomes in diabetes management.
Key Highlights
GLP-1RAs users showed a significant reduction in overall cancer risk (HR = 0.86).
Significant reductions in specific cancer types: pancreatic, colorectal, endometrial, ovarian, hepatocellular, esophageal, and gastric cancers.
No significant associations found for thyroid, breast, kidney, or prostate cancers.
Mechanistic evidence is limited and mostly indirect.
Substantial heterogeneity and reliance on observational evidence warrant cautious interpretation.
Guideline-Based Recommendations
Diagnosis
Evaluate cancer risk in patients with Type 2 Diabetes Mellitus using GLP-1RAs.
Management
Consider GLP-1RAs for glycemic control and cardiometabolic risk reduction.
Monitoring & Follow-up
Monitor cancer outcomes in patients treated with GLP-1RAs.
Risks
Assess potential cancer risks associated with GLP-1RAs, particularly in specific populations.
Patient & Prescribing Data
Adults with Type 2 Diabetes Mellitus.
GLP-1RAs provide metabolic benefits and may reduce cancer risk for certain types.
Clinical Best Practices
Integrate cancer risk assessment in diabetes management plans.
Utilize GLP-1RAs as part of a comprehensive treatment strategy for T2DM.
by Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Abdullateef Isiaka Alagbonsi
